Executive Summary
For sponsors developing RNA therapeutics delivered via lipid nanoparticles (LNPs), quantifying biodistribution and shedding are required components of an IND-enabling data package. A science-based preclinical strategy must characterize both the distribution of the LNP carrier and the persistence of the RNA payload in on-target and non-target tissues. These assessments directly inform the clinical risk profile, dose selection, and regulatory review by agencies like the FDA and EMA, aligning with harmonized ICH guidelines.
Frequently Asked Questions
Q: What are the primary regulatory concerns for biodistribution studies of LNP-delivered RNA therapeutics?
Regulators require a clear understanding of where the LNP and its RNA payload distribute in vivo, particularly in non-target tissues. Key concerns include potential accumulation in organs like the liver, spleen, and reproductive tissues, as well as the potential for off-target biological effects or toxicity. Our IND-enabling toxicology studies are designed to address these points directly.
Q: How are shedding studies for non-viral LNP therapies different from those for viral vectors?
While the principle is the same : to assess the excretion of the therapeutic agent : the specific analytes differ. For LNP systems, quantitative assays like qPCR or ddPCR are developed to detect the RNA payload in excreta (urine, feces) and bodily fluids (saliva, blood). This data is used to evaluate the risk of transmission and environmental exposure, a requirement for GxP-compliant safety packages.
Q: Why is a customized preclinical strategy necessary for each LNP-RNA therapeutic?
A standard testing template does not exist because the biodistribution profile is dictated by the specific chemistry of the ionizable lipids, the size of the nanoparticle, and the nature of the RNA payload (mRNA, siRNA, gRNA). Each unique construct requires a tailored bioanalytical approach to accurately quantify its behavior in vivo and minimize clinical risk.
Characterizing the in vivo fate of lipid nanoparticle (LNP) systems is a required step in advancing RNA therapeutics from discovery to clinical evaluation. The biodistribution profile : where the LNP carrier and its RNA payload accumulate : directly influences both efficacy and the potential for non-target tissue toxicities. This data forms a core component of the safety assessment within any IND or IMPD submission. Our approach to these programs is detailed in our broader [Preclinical and Translational Services](/preclinical-translational-services).
Quantifying Systemic Exposure and Persistence
The design of an LNP can significantly alter its journey through the body. The specific formulation of ionizable lipids, helper lipids, cholesterol, and PEG-lipids determines tissue tropism and clearance rates. A comprehensive preclinical program must dissect the behavior of the complete therapeutic article.
Lessons from other advanced therapy platforms reinforce the need for this diligence. For instance, studies quantifying the whole-body biodistribution of viral vectors have shown that the delivery vehicle can distribute systemically far more than intended, even with targeted administration (PMID: 37624734). This principle of unintended systemic exposure is a significant consideration for LNP developers, as accumulation in non-target organs can lead to unforeseen safety signals.
Our bioanalytical teams develop and qualify phase-appropriate assays to measure payload concentrations in all relevant biological samples, including:
-
Key Tissues: Liver, spleen, lymph nodes, kidneys, heart, and reproductive organs.
-
Biofluids: Plasma, serum, urine, and feces.
-
Target Site: Tumor microenvironments or specific target organs.
Assessing Payload-Driven Toxicity
The biological activity of the RNA payload itself can introduce safety risks independent of the LNP carrier. Previous work with potent RNA modalities has demonstrated that even with effective gene expression knockdown, the therapeutic agent can cause cellular toxicity (PMID: 21542669). This finding underscores the need to evaluate not just the location of the payload, but also its local biological consequences through integrated histology and pathology services.
Within our >100,000 sq ft GxP-compliant facility, we execute these complex studies, integrating in-life observations with downstream bioanalytical and pathology endpoints. This unified operational model supports the 100% successful IND rate our core team of preclinical study directors and principal scientists has maintained since 2019, a track record established prior to the formal launch of Franklin Biolabs in 2024. This approach provides a cohesive data package ready for regulatory submission, often within an 18-24 month timeline. You can explore our facilities here:
.
